See more : Poddar Housing and Development Limited (PODDARHOUS.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Bellerophon Therapeutics, Inc. (BLPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bellerophon Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Vanquis Banking Group plc (FPLPF) Income Statement Analysis – Financial Results
- Pandox AB (publ) (PNDX-B.ST) Income Statement Analysis – Financial Results
- JATT Acquisition Corp (JATT) Income Statement Analysis – Financial Results
- Anglo Pacific Group plc (APY.TO) Income Statement Analysis – Financial Results
- Cerberus Telecom Acquisition Corp. (CTAC) Income Statement Analysis – Financial Results
Bellerophon Therapeutics, Inc. (BLPH)
About Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 65.00K | 102.00K | 147.00K | 348.00K | 362.00K | 373.00K | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -65.00K | -102.00K | -147.00K | -348.00K | -362.00K | -373.00K | -400.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.36M | 13.02M | 17.89M | 11.03M | 20.26M | 17.85M | 16.65M | 33.37M | 45.98M | 52.99M | 38.73M |
| General & Administrative | 6.02M | 7.15M | 8.39M | 6.44M | 7.62M | 6.75M | 7.11M | 14.87M | 0.00 | 9.01M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.02M | 7.15M | 8.39M | 6.44M | 7.62M | 6.75M | 7.11M | 14.87M | 13.78M | 9.01M | 7.19M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -674.00K | 27.88M | 24.60M | 23.76M | 48.24M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.38M | 20.16M | 26.28M | 17.47M | 27.88M | 24.60M | 23.76M | 46.57M | 59.75M | 62.00M | 46.23M |
| Cost & Expenses | 22.38M | 20.16M | 26.28M | 17.47M | 27.88M | 24.60M | 23.76M | 46.57M | 59.75M | 62.00M | 46.23M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 378.00K | 184.00K | 95.00K | 109.00K | 79.00K | 0.00 | 0.00 |
| Interest Expense | 135.00K | 5.00K | 250.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 65.00K | 102.00K | 147.00K | 348.00K | 362.00K | 373.00K | 400.00K | 377.00K | 388.00K | 429.00K | 85.00K |
| EBITDA | -22.18M | -20.16M | -26.71M | -14.72M | -2.26M | -54.45M | -23.85M | -46.08M | -59.37M | -61.57M | -46.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.38M | -20.16M | -26.28M | -17.47M | -27.88M | -24.60M | -23.76M | -46.57M | -59.75M | -62.00M | -46.23M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 136.00K | 605.00K | -577.00K | 2.41M | 25.26M | -30.22M | -495.00K | 402.00K | 79.00K | 0.00 | 0.00 |
| Income Before Tax | -22.25M | -19.56M | -26.85M | -15.07M | -2.63M | -54.82M | -24.25M | -46.46M | -59.67M | -62.00M | -46.23M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.42M | -1.80M | -2.13M | -1.80M | -5.44M | 29.85M | -438.00K | 1.18M | 0.00 | 0.00 | 0.00 |
| Net Income | -19.83M | -17.76M | -24.73M | -13.27M | 2.81M | -54.82M | -23.81M | -46.46M | -59.67M | -62.00M | -46.23M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.08 | -1.87 | -3.17 | -2.95 | 0.65 | -21.11 | -23.72 | -56.81 | -5.01 | -4.80 | -3.58 |
| EPS Diluted | -2.08 | -1.87 | -3.17 | -2.95 | 0.65 | -21.11 | -23.72 | -56.81 | -5.01 | -4.80 | -3.58 |
| Weighted Avg Shares Out | 9.55M | 9.50M | 7.80M | 4.50M | 4.34M | 2.60M | 1.00M | 817.85K | 11.91M | 12.91M | 12.91M |
| Weighted Avg Shares Out (Dil) | 9.55M | 9.50M | 7.80M | 4.50M | 4.34M | 2.60M | 1.00M | 817.85K | 11.91M | 12.91M | 12.91M |
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Bellerophon Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm
Robbins Arroyo LLP is Investigating the Officers and Directors of Bellerophon Therapeutics, Inc. (BLPH) on Behalf of Shareholders
INVESTOR ALERT: Investigation of Bellerophon Therapeutics, Inc. Announced by Law Offices of Howard G. Smith
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Bellerophon Therapeutics LLC and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws
Source: https://incomestatements.info
Category: Stock Reports